Live Breaking News & Updates on Blue Earth Therapeutics

Stay updated with breaking news from Blue earth therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Shine Technologies Partners with Blue Earth Therapeutics for First Supply of Ilumira from Its New Facility

Blue Earth Therapeutics will leverage Shine's non-carrier added lutetium-177 chloride, Ilumira, in a new treatment for prostate cancer undergoing clinical trials ....

United States , David Gauden , Shine Technologies , American Cancer Society , Drug Administration , Blue Earth Therapeutics , Drug Master File , Earth Therapeutics , North America , Blue Earth , Greg Piefer ,

Blue Earth Diagnostics Highlights Presentations on POSLUMA (Flotufolastat F 18), Axumin (Fluciclovine F 18) and Investigational 18F-Flotufolastat/18F-rhPSMA-7 at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced upcoming presentations by its collaborators ....

United Kingdom , United States , Markt Schwaben , Davide Gauden , Sean Collins , Clare Gidley , Priscilla Harlan , Isabel Rauscher , Ismaheel Lawal , Nadine Mallak , Elizabeth Hawk , Mike Beyer , Todd Cohen , Science University , Bracco Group , Georgetown University Hospital , Department Of Radiology , Nuclear Medicine , Emory University , Blue Earth Diagnostics Inc , Corporate Communications , School Of Medicine , Department Of Nuclear Medicine , Oregon Health , Blue Earth Diagnostics Ltd , Imaging Sciences ,

Blue Earth Diagnostics Announces Agreement with Siemens Healthineers to Share PET Imaging Agent POSLUMA (Flotufolastat F 18) Clinical Data to Support AI-based Algorithms Development

Blue Earth Diagnostics Announces Agreement with Siemens Healthineers to Share PET Imaging Agent POSLUMA (Flotufolastat F 18) Clinical Data to Support AI-based Algorithms Development
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United Kingdom , United States , Mike Beyer , Bruce Spottiswoode , Scintomics Gmb , David Gauden , Clare Gidley , Priscilla Harlan , Siemens Healthineers , A Siemens Healthineers Company , Technical University Of Munich , Bracco Group , Sam Brown Inc , Nuclear Medicine , Blue Earth Diagnostics Ltd , Solutions Inc , Drug Administration , Corporate Communications , Clinical Applications Research , Earth Diagnostics , Blue Earth Diagnostic Phase , Prostate Specific Membrane Antigen Targeted , Business Wire , Chief Executive Officer , Blue Earth , Siemens Healthineers Company ,

Blue Earth Diagnostics Announces Agreement with Siemens Healthineers to Share PET Imaging Agent POSLUMA® (Flotufolastat F 18) Clinical Data to Support AI-based Algorithms Development

Blue Earth Diagnostics Announces Agreement with Siemens Healthineers to Share PET Imaging Agent POSLUMA® (Flotufolastat F 18) Clinical Data to Support AI-based Algorithms Development
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United States , Siemens Healthineers , Scintomics Gmb , David Gauden , Bruce Spottiswoode , Technical University Of Munich , Bracco Group , Blue Earth Diagnostics Ltd , Solutions Inc , Clinical Applications Research , Nuclear Medicine , A Siemens Healthineers Company , Drug Administration , Clinical Data To Support Algorithms Development , Earth Diagnostics Announces Agreement , Clinical Data , Earth Diagnostics , Blue Earth Diagnostic Phase , Prostate Specific Membrane Antigen Targeted , Business Wire , Chief Executive Officer , Blue Earth , Siemens Healthineers Company , Blue Earth Diagnostics , Radiohybrid Prostate Specific Membrane Antigen , Prostate Specific Membrane Antigen ,

Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

177Lutetium-labeled radiohybrid Prostate-Specific Membrane Antigen (177Lu-rhPSMA-10.1) is in development as a highly optimized, next generation therapeutic radiopharmaceutical ....

United States , San Diego , Davide Gauden , Scintomics Gmb , Technical University Of Munich , American Association For Cancer Research , Blue Earth Therapeutics , American Association , Cancer Research , Annual Meeting , Prostate Specific Membrane Antigen Targeted , Blue Earth Therapeutic , Chief Executive Officer , Blue Earth , Radiohybrid Prostate Specific Membrane Antigen , Technical University , Blue Earth Diagnostics , Scintomics Gmbh ,